A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
ObjectiveThe purpose of this study was to initially investigate the effect of previous antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients with advanced or metastatic lung cancer (LC).MethodsWe retrospectively collected the clinical data of patients with LC t...
Main Authors: | Jiaojiao Suo, Yu Sun, Yan Fu, Weigang Xiu, Xuanwei Zhang, Yan Wang, Jiang Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.788837/full |
Similar Items
-
A phase II study of anlotinib combined with etoposide and platinum‐based regimens in the first‐line treatment of extensive‐stage small cell lung cancer
by: Chang Liu, et al.
Published: (2022-05-01) -
Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
by: Lian Yu, et al.
Published: (2023-03-01) -
Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
by: Yu Fang, et al.
Published: (2023-11-01) -
Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
by: Hao YY, et al.
Published: (2021-12-01) -
Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review
by: Xiaomeng Zou, et al.
Published: (2023-02-01)